(NYSE: BIO) Bio Rad Laboratories's forecast annual revenue growth rate of 2.82% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 9.06%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.32%.
Bio Rad Laboratories's revenue in 2026 is $2,583,200,000.On average, 7 Wall Street analysts forecast BIO's revenue for 2026 to be $71,632,505,676, with the lowest BIO revenue forecast at $69,014,437,458, and the highest BIO revenue forecast at $74,952,324,138. On average, 7 Wall Street analysts forecast BIO's revenue for 2027 to be $73,818,727,590, with the lowest BIO revenue forecast at $70,687,841,886, and the highest BIO revenue forecast at $77,975,248,266.
In 2028, BIO is forecast to generate $75,735,045,564 in revenue, with the lowest revenue forecast at $72,523,188,678 and the highest revenue forecast at $79,594,671,906.